Back to Search Start Over

J&J seeks EU approval of nipocalimab to treat people living with generalised myasthenia gravis

Source :
PharmaBiz. September 14, 2024
Publication Year :
2024

Abstract

Janssen-Cilag International NV, a Johnson & Johnson company, announced the submission of the Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking first approval of nipocalimab for the [...]

Subjects

Subjects :
United States. Food and Drug Administration
Johnson & Johnson
Viral antibodies -- Research
Myasthenia gravis -- Care and treatment -- Research
Antibodies -- Research
Pharmaceutical industry -- Research
Pharmaceuticals and cosmetics industries

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.808623604

Tools

Authors Abstract Subjects Details